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PANCREATIC RIBONUCLEASE FUNCTIONS AS AN EPIDERMAL GROWTH 
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Heng-Huan Lee, M.S. 
Supervisory Professor: Mien-Chie Hung, Ph. D. 
 
Ribonuclease (RNase) with its catalytic enzyme activity to degrade RNAs has 
been shown as a diagnostic serum marker for pancreatic cancer and has also been 
suspected to have an unidentified cell surface receptor. Epidermal growth factor 
receptor (EGFR), a well-characterized receptor tyrosine kinase is an effective 
therapeutic target in multiple cancer types. However, clinical trials targeting EGFR 
have not demonstrated improved therapeutic efficacy in pancreatic cancer. Here, 
we show that both bovine pancreatic RNase A (bRNaseA) and human RNase 5 
(hRNase5) act as EGFR ligands and directly activate EGFR to promote epithelial-
mesenchymal transition. This ligand-like activity is independent of RNases’ 
enzymatic activity. In addition, Gln93 and Tyr94 of hRNase5, which are highly 
conserved between hRNase5 and EGF, are critical for efficient binding to EGFR. A 
statistically positive correlation between hRNase5 and activated EGFR expression 
in human pancreatic tissue microarrays further supports the pathological relevance 
of hRNase5. Strikingly, hRNase5 also enhances resistance to cetuximab therapy in 
pancreatic cancer. Thus, there may be an interplay between serum RNase and 
overexpressed EGFR in human cancers, especially in pancreatic cancer, that leads 
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to aggressive cancer behaviors. Our findings uncover a potential opportunity for 
therapeutic intervention by rational combination therapy of hRNase5 inhibition and 
cetuximab.  
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1.1 Structural perspective of EGFR and its family members 
Growth factors and their cognate receptors play essential roles in governing life 
and death of cells and organisms. Among them, the epidermal growth factor 
receptor (EGFR/ErbB1/HER1) and its family members including ErbB2 (HER2/Neu), 
ErbB3 (HER3) and ErbB4 (HER4), have long been recognized as a primordial type 
of receptor tyrosine kinases which contribute to key steps in both human physiology 
and diseases (Hynes & Lane, 2005; Lemmon & Schlessinger, 2010). As single 
chain transmembrane glycoproteins, the epidermal growth factor receptor family 
preserves structural resemblance within its four members, which are composed of 
an N-terminal extracellular ligand-binding ectodomain, a lipophilic transmembrane 
domain, a short juxtamembrane region, a tyrosine kinase domain and a tyrosine-
rich regulatory domain at C-terminal. To date, both EGFR and HER4 are reported 
as complete functional receptor tyrosine kinases with corresponding ligands and 
functional tyrosine kinase domains. However, HER2 is an orphan receptor without 
cognate ligands found so far (Brennan et al., 2000), and HER3 is not a functional 
tyrosine kinase since it loses intrinsic kinase activities (Guy et al., 1994). The N-
terminal extracellular domain can be further divided into four subdomains which are 
L1 (Leucine-rich/domain I), CR1 (Cysteine-rich/domain II), L2 (Leucine-rich/domain 
III) and CR2 (Cysteine-rich/domain IV) in a linear order from N- to C-terminal. 
Domain I and III are responsible for direct ligand binding to receptors, whereas 
domain II and IV constitute dimerization loop and contribute to receptor-receptor 
interaction. Without ligand stimulation, domain II and IV are bound with each other 
through intramolecular binding, this interaction forces the receptor in a closed and 
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inactive monomer conformation which can keep domain I and III away from 
extracellular ligands. However, in the presence of a soluble ligand, domain I and III 
can be bound by the ligand in a direct manner, this conformational change can 
remove the intramolecular interaction between domain II and IV and shift a receptor 
from a closed and inactive conformation to an open and active orientation. In an 
open and active orientation, the dimerization region from domain II of one receptor 
can be exposed and associated with the other receptor at the same region to further 
facilitate the formation of a receptor dimer. The balance between the open and 
closed conformation of a receptor is usually kept at steady state and can be 
modulated by a variety of ligands binding to switch monomeric receptors to become 
either homo-dimers or hetero-dimers, depending on the type of ligands and 
corresponding receptors (Eccles, 2011). 
 
1.2 Endocytic trafficking of EGFR 
When receptors are bound by ligands to cause their conformational change and 
dimerization, they will be further internalized as vesicles and undergo endosomal 
sorting and trafficking to different subcellular location inside the cell (Conner & 
Schmid, 2003; Doherty & McMahon, 2009; Sorkin & von Zastrow, 2009). 
Internalization of receptors can occur through clathrin-dependent or clathrin-
independent pathways to form vesicles, followed by adaptor proteins (AP2) and 
growth factor receptor-bound protein 2 (Grb2) binding and fusion with early 
endosomes (Mayor & Pagano, 2007; Orth et al., 2006; Sigismund et al., 2005; 
Sorkin, 2004). Concomitant recruitment of E3 ubiquitin ligase Cbl to receptors 
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through direct or indirect binding (Grb2-dependent) will catalyze receptor 
ubiquitination in either monomeric or polymeric forms on certain lysine residues of 
their kinase domain, which can be further recognized by ubiquitin-binding proteins 
such as epsin1 and Eps15 for subsequent sorting and targeting through endosomal 
sorting complex required for transport (ESCRT) within multivesicular bodies and 
subject to lysosomal degradation (Gruenberg & Stenmark, 2004; Saftig & 
Klumperman, 2009; Sorkin & Goh, 2009; Williams & Urbe, 2007; Woodman, 2009). 
Under certain circumstances such as pH-dependent decreased stability of ligand-
receptor complex or AMSH-mediated deubiquitination process, activated receptors 
can go through recycling pathway to escape from lysosomal degradation (Baldys & 
Raymond, 2009). As reported by previous studies, recycling of receptor kinases can 
occur via Rab4- and Rab35-dependent pathway to plasma membrane or Rab11-
regulated route through perinuclear endocytic recycling compartment (ERC) 
(Ceresa, 2006; Grant & Donaldson, 2009; Maxfield & McGraw, 2004). Increased 
receptor recycling instead of lysosomal degradation after its activation may prolong 
its signaling duration and succeeding mitogenic effects.  
Notably, a growing body of evidence has shown that other than traditional 
routes to lysosomal degradation and endocytic recycling, EGFR and other 
membrane receptors can undergo nuclear translocation through a retrograde 
pathway (Brand et al., 2013; Carpenter & Liao, 2009; Lin et al., 2001; Lo, 2010; 
Massie & Mills, 2006; Mosesson et al., 2008; Ni et al., 2001; Offterdinger et al., 
2002; Seshacharyulu et al., 2012; Wang & Hung, 2012; Wang et al., 2010a). Inside 
the nucleus, EGFR can serve as a kinase, transcription factor or protein scaffold to 
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modulate nuclear signaling and gene expression. This alternative route of EGFR to 
nucleus can contribute to DNA repair, replication of tumor cells and confer 
resistance to chemo- and radio-therapies (Dittmann et al., 2011; Huang et al., 2011; 
Huang & Hung, 2009; Wang et al., 2006; Wang et al., 2010b). In addition, nuclear 
EGFR has the clinical relevance to be associated with poor patient prognosis in 
diverse cancers, including breast, ovarian, and oropharyngeal and esophageal 
squamous cell cancers (Hadzisejdic et al., 2010; Hoshino et al., 2007; Lo et al., 
2005; Psyrri et al., 2008; Psyrri et al., 2005; Xia et al., 2009) (Figure 1-1). 
 
1.3 Ligands of ErbB family 
A group of ligands are known to activate ErbB family members including EGF, 
transforming growth factor alpha (TGF-α), amphiregulin (AR), betacellulin (BTC), 
heparin-binding EGF-like growth factor (HB-EGF), epiregulin (EPR), epigen (EPG), 
neuregulins 1-4 (NRGs), neuroglycan C (NGC) and tomoregulin (TR) (Citri & 
Yarden, 2006; Harris et al., 2003). These ligands are expressed as plasma 
membrane-anchored precursor proteins and are processed to mature forms via 
proteolytic release by certain metalloproteinase such as TACE/ADAM17 and 
ADAM10, etc (Nakamura et al., 1995). Among them, EGF, TGF-α, AR and EPG are 
specific ligands to EGFR, whereas BTC, HB-EGF and EPR can bind to both EGFR 
and HER4. Moreover, NGC is a specific ligand to HER3, and both NRG3 and NRG4 
are particular ligands to HER4. NRG1 and NRG2 can bind to either HER3 or HER4. 
To date, there is no specific ligand found for HER2 and its activation are reported to 
be caused by either receptor overexpression or heterodimerization with another  
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Figure 1-1. ERBB trafficking.  
Exposing the cell to epidermal growth factor (EGF) results in the 
autophosphorylation of surface EGF receptor (EGFR), which might result in EGFR 
moving out of lipid rafts. This activation also results in the ubiquitylation of the 
receptor and its removal (endocytosis) from the cell surface into an early endosomal 
compartment. The ligand-bound receptor activates several signaling pathways at 
the cell surface by activating Ras and phospholipase Cγ (PLCγ). EGFR interacts 
with and activates signalling molecules while its cytoplasmic tail projects into the 
cytoplasm, as occurs in the early endosome. From the early endosome the receptor 
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can be recycled back to the cell surface (a) or sorted into the late endosome and 
the vesicles within this compartment that are called multivesicular bodies (b). If 
sorted into multivesicular bodies, the cytoplasmic tail is occluded from the 
cytoplasm and this prevents further activation of signalling cascades. Following a 
fusion event between the late-endosomal and lysosomal compartments the 
internalized receptor is incorporated into the lysosome and degraded. A third 
possibility is that, having been internalized and incorporated into the early 
endosome, the receptor is delivered to the nucleus (c). The route that is taken to the 
nucleus by ERBBs is unclear, but might include proteolytic cleavage, membrane 
fusion or chaperone-mediated dissociation of the receptor from the membrane. This 
is potentially a direct route to mediate changes in gene expression and DNA repair 
in response to stimuli. Nuclear translocation is also a property of certain adaptor 
proteins that are associated with early endosomes, including APPL (adaptor protein 
containing a pleckstrin homology domain, a PTB domain and a leucine zipper motif) 
and HIP1 (huntingtin-interacting protein 1). Additional, and less-common, trafficking 
routes for cargo arriving in the early endosome include retrograde trafficking steps 
to compartments such as the endoplasmic reticulum (ER) and Golgi apparatus that 
are associated with the biosynthesis and post-translational modification of proteins. 
Viruses and toxins commonly use these trafficking routes to ultimately gain access 
to the cytoplasm by expulsion from the ER. P, phosphate; Ub, ubiquitin. (This figure 
was adapted from MASSIE, C. & MILLS, I. G. (2006). The developing role of 
receptors and adaptors. Nat Rev Cancer, 6(5), 403-409; the permission was 
received from the journal.) 
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receptors including EGFR, HER3 or HER4 through their corresponding ligand 
binding and stimulation (Harris et al., 2003) (Figure 1-2). 
 
1.4 Activation of EGFR signaling 
Dimerization of receptors leads to their auto-phosphorylation on particular 
tyrosine residues through a reciprocal manner, further recruiting protein adaptors, 
effector proteins and kinase substrates to trigger downstream signaling network. To 
initiate the phosphotyrosine-based signaling cascade, phosphotyrosine residues 
from a receptor kinase are specifically recognized by a Src homology 2 (SH2) and 
phosphotyrosine-binding domain from an adaptor protein. This phosphotyrosine-
based molecular recognition can lead to adaptor and effector proteins 
phosphorylation and elevate their activities, further provoking subsequent 
occurrence of signaling events including the RAS-RAF-MEK-ERK pathway, 
phosphoinositide 3-kinase (PI3K)-AKT (Protein kinase B/PKB) signaling, 
phospholipase C gamma (PLCγ)-protein kinase C (PKC) pathway, and signal 
transducer and activator of transcription (STAT) activation (Yarden, 2001). These 
signaling pathways act as mediators amplify and transmit the original stimuli from 
the receptor at plasma membrane to intracellular space including cytosol and 
subcellular organelles, eventually to the nucleus to regulate DNA replication, gene 
transcription and translation, etc. Through these signaling cascades and molecular 
interaction events, an ErbB receptor-triggered signaling can modulate and 
contribute to normal cellular events including proliferation, migration, differentiation, 
development, etc (Citri & Yarden, 2006; Huang et al., 2009). On the other hand, its  
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Figure 1-2. Heterodimerization, ligand binding and signaling in the EGFR and 
ERBB family.  
(a) EGFR is a 170 kDa transmembrane protein of the HER family of receptors. Each 
receptor contains an extracellular ligand-binding domain, a transmembrane 
lipophilic domain and an intracellular tyrosine kinase domain and, except for HER3, 
relies upon heterodimerization for transphosphorylation. No ligand for HER2 has 
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been identified. Ligand binding induces autophosphorylation and causes activation 
of downstream signaling pathways. Ligands are indicated by circles, PI3K binding 
sites are indicated by red squares. (b) Diagram of EGFR protein. The extracellular 
domain of EGFR comprises 621 amino acids and consists of four different subunits, 
RI–RIV. RI is important in ligand-induced dimerization; RII and RIV are rich in 
cysteine residues. RIII includes the EGF-binding domain. The intracellular region 
contains the tyrosine kinase domain and the C-terminus, which has six 
autophosphorylation sites. (c) The most widely known and best-characterized RAS 
signaling pathways include MAPK–ERK, the MAPK–JNK and p38 pathways. MAPK 
cascades are activated through a large variety of extracellular signals, including 
growth factors, differentiation factors and stress-induced factors. Abbreviations: HB-
EGF, heparin-binding EGF-like growth factor; TM, transmembrane region. (This 
figure was adapted from LINARDOU, H., DAHABREH, I. J., BAFALOUKOS, D., 
KOSMIDIS, P. & MURRAY, S. (2009). Somatic EGFR mutations and efficacy of 
tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol, 6(6), 352-366; the 
permission was received from the journal.) 
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dysregulation can lead to multiple types of human malignancies and diseases, 
including cancers. 
 
1.5 EGFR genetic alterations in cancers 
Enormous studies and clinical evidence have demonstrated that EGFR plays a 
key role in various types of cancer development, including lung, head and neck, 
breast, ovarian, colon and pancreatic cancers, etc. Ectopic expression of EGFR can 
lead to transformation of mouse NIH3T3 cells in vitro through ligand-dependent 
manner. Blockage of EGFR signaling impedes growth of multiple types of cancer 
cells both in vitro and in vivo. Genetic alternations of EGFR such as gene 
amplification or somatic mutation are frequently observed in both clinical samples 
and tumor cell lines derived from patients with different types of cancers. In average, 
EGFR gene amplification can be detected in about 40% of human primary 
glioblastoma multiforme (GBM) (Hatanpaa et al., 2010; Lopez-Gines et al., 2010) 
and 5-10% Non-small cell lung cancer (NSCLC) (Gazdar, 2009; Linardou et al., 
2009). Activating deletions of EGFR have also been found in a significant 
population of GBM patients and associated with poor prognosis. N-terminal 
truncations and deletions of EGFR are reported including EGFRvI (N-terminal 
truncation), EGFRvII (exon 14-15 deletion), EGFRvIII (exon 2-7 deletion), EGFRvIV 
(exon 25-27 deletion) and EGFRvV (C-terminal truncation). Among them, EGFRvIII 
is a major mutant which is known to play a key role in GBM pathogenesis 
(Shinojima et al., 2003). In addition, it can be also detected in breast, ovarian, 
prostate and lung cancers and participated in cancer progression. Activating 
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mutations of EGFR kinase domain are also identified in 10-20% NSCLCs including 
missense mutations (L858R, G719X and L861Q), in frame deletion of exon 19 or 
insertion of exon 20, etc (Wieduwilt & Moasser, 2008). 
 
1.6 EGFR-targeted therapies in cancers 
Due to its integral role in the pathogenesis of different types of tumors, inhibition 
of EGFR signaling as a target therapy is developed for years and proved powerful in 
certain clinical settings (Tomas et al., 2014). Both EGFR-specific monoclonal 
antibodies (mAbs) and chemical compounds as EGFR tyrosine kinase inhibitors 
(TKIs) are approved and prevalently used in clinics for different types of cancers 
(Chong & Janne, 2013; Eccles, 2011; Wheeler et al., 2010). EGFR-specific mAbs 
such as cetuximab (Erbitux/C225) and panitumumab (Vectibix) are generated to 
bind to EGFR extracellular domain for preventing from their cognate ligand binding.  
C225 is commonly used in colon cancers with wild type KRAS status, and it is also 
applied in head and neck cancers which possess EGFR overexpression with higher 
frequency (Mendelsohn & Baselga, 2000). On the other hand, the TKIs gefitinib 
(Irresa) and erlotinib (Tarceva) are both actively applied in the clinical treatment of 
NSCLC patients with EGFR activating mutations. Higher response rate and 
extended survival time are reported for NSCLC patients with EGFR activating 
mutations compared to those who do not have mutations treated with TKIs 
(Seshacharyulu et al., 2012). In summary, several lines of evidence and studies 
have suggested that application of anti-EGFR agents to certain types of tumors 
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including colon, head and neck, NSCLC and pancreatic cancer confers benefits and 
advantages in terms of overall survival or progression-free survival. 
 
1.7 The role of EGFR in pancreatic cancer 
Human pancreatic cancer, attributed to its high mortality rate and poor clinical 
outcome, currently ranks fourth as cancer death cause in the United States. Due to 
the early metastasis, late diagnosis and refractory to canonical therapies including 
chemotherapy and radiotherapy, pancreatic cancer especially pancreatic ductal 
adenocarcinoma (PDAC) is recognized as one of the most lethal malignancies 
among human cancers in the last decades (Hidalgo, 2010). Massive efforts have 
been made to characterize critical genetic alternation and signaling pathways 
occurring with PDAC development. Based on genetic studies and transgenic mouse 
models, it is believed that KRAS and INK4A mutation occur in the early stage of 
PDAC development; follow by alternation of SMAD4 and p53 tumor suppressors 
(Lunardi et al., 2014). Notably, two decent papers have recently reported that EGFR 
is required for tumor initiation and development based on PDAC transgenic mouse 
models (Ardito et al., 2012; Navas et al., 2012). EGFR depletion can impede PDAC 
tumorigenesis in KRASG12D and CDKN2Aflox mice, whereas it doesn’t affect 
KRASG12D-driven lung cancer progression. Interestingly, EGFR overexpression in 
advanced pancreatic cancer is present from 30% to 95% depending on cases 
examined. Moreover, several lines of evidence suggest that EGFR or EGF 
expression has been found to be positively associated with PDAC metastasis in a 
significant level. These previous research work point out EGFR may play a critical 
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role in PDAC tumor initiation and contribute to its development and metastasis. 
However, how EGFR signaling regulates PDAC progression remains unclear and its 
clinical impact awaits more follow-up studies and clinical trials to delineate. To date, 
four Phase III trials in advanced PDAC using anti-EGFR target therapies combined 
with conventional chemotherapeutic agents including gemcitabine or capecitabine 
were completed (Heinemann et al., 2013; Moore et al., 2007; Philip et al., 2010; Van 
Cutsem et al., 2009). The benefits from EGFR-targeted therapy are limited, and it 
remains to be further pursued if it can be improved in the aid of certain predictive 
biomarkers. 
 
1.8 Bovine pancreatic RNase A  
As a most well studied enzyme in 20th century and so far, bovine pancreatic 
ribonuclease A (RNase A) has been established as a model system for research of 
protein chemistry, enzymology and structure biology, etc. Ribonuclease A was first 
identified by Ren’e Dubos in 1938, crystallized by Moses Kunitz’s group in 1940, 
sequenced by Stanford Moore and William Stein in 1963 (through cooperation with 
Anfinsen’s group), and synthesized through solid-phase by Merrifield’s group in 
1969. Four Nobel Prizes were awarded (Anfinsen, Moore, Stein and Merrifield) for 
their comprehensive and excellent work at RNase studies (Marshall et al., 2008; 
Raines, 1998). RNase A is a pancreatic endonuclease which is secreted from β 
cells at the islets of Langerhans. It can cleave phosphodiester bond at single strand 
RNA between the 5’-ribose of a nucleotide and the phosphate group on a 3’-ribose 
of the neighboring pyrimidine nucleotide, and further hydrolyze the formed 2’-3’-
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cyclic phosphate intermediate to generate 3’-nucleoside phosphate. It exerts 
substrate preference for different bases on both 5’- and 3’-end of the broken 
phosphodiester bond. At the 5’-position, RNase A displays higher enzymatic 
efficiency in an order as A>G>C>U, whereas at the 3’-position, a pyrimidine is 
required to be present and C is favored than U. Being a secretory enzyme produced 
from pancreas, RNase A possess signal peptide on the very N-terminal (1-26 of 
precursor protein) which is responsible for its secretion to extracellular space. In 
native RNase A protein, there are four pairs of disulfide bonds (Cys26-Cys84, 
Cys40-Cys110, Cys58-Cys110 and Cys65-Cys72) which contribute to its protein 
folding and stability. The mature form of RNase A protein (124 amino acids) 
contains a catalytic triad constituted ty amino acid residue His12, Lys41, and His119, 
where His12 and His119 acts as a respective proton acceptor and donor, and Lys41 
can provide a hydrogen bond to stabilize the transition state during catalysis 
(Cuchillo et al., 2011).  
 
1.9 Human RNase A family 
In last decades, a family of vertebrate secretory ribonucleases with sequence 
and structure homology to bovine RNase A has been found from the human 
genome. In general, they are recognized as part of host defense system and 
contribute to immunity especially innate immunity. To date, there are 13 
ribonucleases are identified for the RNase A family which are produced and 
secreted from various types of cell types including epithelial, endothelial and 
immune cells, etc (Cho et al., 2005). Among them, human RNase 1 is the direct 
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homologue of bovine RNase A according to their sequence and structure similarity 
(Peracaula et al., 2000). The RNase A family can be divided into two groups; the 
canonical ribonucleases (RNase 1-8) and non-canonical ribonucleases (RNase 9-
13) (Sorrentino, 2010). In the group of canonical ribonucleases, they maintain 
classical signal sequences for secretion, particular disulfide-bonded secondary and 
tertiary structure, conserved active sites and His-Lys-His catalytic triad to exhibit 
certain degree of catalytic activity against single strand RNA substrate (Cuchillo et 
al., 2011; Yang et al., 2004). On the other hand, the non-canonical ribonucleases do 
not act as functional enzymes because they encode either insertions, deletions or 
mutation at certain essential residues although they still exert microbicidal activities 
and contribute to host defense system (Cho et al., 2005; Sorrentino, 2010).  
 
1.10 RNases in cancers 
In addition to being participants in host defense system, expression of 
ribonucleases have been demonstrated to be positively associated with cancer 
occurrence and progression. Elevated ribonuclease activities were detected in 
several types of cancers including lung, thyroid, breast, ovarian, kidney, colon and 
pancreatic cancer (Matte et al., 2012; Reddi & Holland, 1976; Tello-Montoliu et al., 
2006). Compared to other types of cancers, pancreatic cancer is one of the most 
studied malignancies with this observation since numerous studies have indicated 
higher ribonuclease activities can be measured in patient serum compared to 
control samples. Accordingly, ribonuclease activity was proposed to serve as early 
diagnostic marker for pancreatic cancer in several studies (Kottel et al., 1978; 
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Warshaw et al., 1980; Zhao et al., 1998) although some researchers argued it lacks 
specificity to be useful. In addition to ribonuclease activities, specific members of 
RNase A family including human RNase 1 and RNase 5 were reported to be 
involved in the development of pancreatic cancer (Peracaula et al., 2000; Poon et 
al., 2001; Reddi & Holland, 1976). Both human RNase 1 and RNase 5 protein can 
be detected in the culture medium of pancreatic cancer cells, and specific isoforms 
of human RNase 1 with distinct glycosylation pattern were merely detected in tumor 
cell lines (Peracaula et al., 2003). Moreover, increased human RNase 5 was 
correlated with pancreatic cancer occurrence and aggressiveness (Shimoyama et 
al., 1996). In contrast to other members in the RNase A family, accumulated studies 
have concluded human RNase 5 as an oncogenic protein which can induce blood 
vessel formation in vitro and in vivo (Hu et al., 1997; Li et al., 2011; Yoshioka et al., 
2006). Because its potency to promote angiogenesis, it is also named angiogenin.  
 
1.11 Human RNase 5 (angiogenin) 
Human RNase 5 (angiogenin) was first isolated from culture medium of a 
human colon cancer cell line HT-29. Like other RNase A family members, human 
RNase 5 exhibits microbicidal function to protect from pathogen infection. However, 
it is also a potent factor to stimulate angiogenesis . It is a close homologue of 
human RNase 1 with 33% in sequence identity and 65% homology. Human RNase 
5 contains a classical secretory signal sequence (1-24 of a precursor protein) and a 
conserved catalytic triad (His13, Lys40 and His114 of the mature form with 123 
amino acids) (Padhi et al., 2012; Strydom, 1998). In spite of its high similarity to 
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human RNase 1 in tertiary structure, human RNase 5 exerts much lower enzymatic 
activity than RNase 1 (105 -106 less in average) (Cho et al., 2005; Sorrentino, 2010). 
However, it is demonstrated that ribonuclease activity is essential but not sufficient 
for human RNase 5-induced angiogenesis (Hu, 1998). Its expression is increased 
during inflammation, pregnancy and certain pathological conditions. Moreover, it 
was showed that its expression is elevated in several malignant diseases and 
multiple types of cancers including colon, prostate, ovarian and pancreatic cancer 
(Matte et al., 2012; Tello-Montoliu et al., 2006). Several lines of evidence suggests 
human RNase 5 can increase endothelial cell migration and proliferation through 
initiating intracellular signaling pathways, such as PLCγ, AKT and ERK activation 
(Kim et al., 2007; Liu et al., 2001). Previous studies also showed that after entry into 
recipient cells, human RNase 5 can translocate to nucleus and increase rRNA 
transcription (Ibaragi et al., 2009; Moroianu & Riordan, 1994). Correspondingly, 
nuclear translocation of human RNase 5 is required for its provoked endothelial cell 
proliferation and angiogenesis. To search for a potential surface receptor bound by 
human RNase 5, researchers have demonstrated that human RNase 5 can bind to 
α-actinin-2 on the surface of smooth muscle cells to promote their proliferation (Hu 
et al., 2005). In addition, α-actin and 170-kDa cell surface receptor from endothelial 
cells were identified to be a binding partner of human RNase 5 (Hu et al., 1997). 
Binding to α-actin can lead to proteolytic activation, which may contribute to 
basement membrane degradation (Hu et al., 1993). It is believed that this 170-kDa 
surface receptor could be critical for human RNase 5-provoked signaling and 
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angiogenic function. However, the identity of this receptor remains ambiguous and 
awaits more studies to resolve the puzzle.  
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Chapter 2 
Material and Methods 
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2.1 Materials  
The following antibodies and chemicals were purchased commercially: anti-
EGFR antibodies (Ab-13, Thermo Scientific; 4267, Cell Signaling; ab62, Abcam); 
AG1478, mouse IgG, bovine RNase A (bRNaseA), human EGF, anti-RNase1, actin, 
and tubulin antibodies (Sigma); anti-bRNaseA (ab6611) and bRNaseA biotinylated 
(ab20588) antibodies (Abcam); anti-myc antibody (Roche); anti-flag antibodies 
(Sigma; Cell Signaling); TMB (3,3',5,5"-tetramethylbenzidine) substrate, stop 
solution, anti-Akt, phospho-Akt, phospho-ERK1/2, phospho-EGFR (-Tyr992, -
Tyr1045, -Tyr1068, -Tyr1086, -Tyr1148, and -Tyr1173), phospho-ErbB2 (-
Tyr1221/1222 and -Tyr1248), EMT (Slug, Snail, E-cadherin, N-cadherin, Vimentin, 
and ZEB-1), and GST antibodies (Cell Signaling); anti-ErbB-2 (Calbiochem); ELISA 
96-well plate, BSA blocking solution, and anti-p68 RNA helicase antibody (Santa 
Cruz Biotechnology); anti-phosphotyrosine (p-Tyr; 4G10) and ERK1/2 antibodies 
(Millipore); recombinant human RNase 5/angiogenin, recombinant human 
EGFR/ErbB1 Fc Chimera (N-EGFR-Fc), Proteome Profiler Human Phospho-RTK 
Array Kit, Streptavidin-HRP, anti-angiogenin (AB-265-NA), angiogenin biotinylated 
(BAF265), EGF, and EGF biotinylated (BAF236) antibodies (R&D Systems); 
gefitinib (ChemieTek); erlotinib (LC Labs); biotin-EGF and SYTO® RNASelectTM 
green-fluorescent cell stain (Invitrogen); and DyLight 594 labeling kit (Thermo 
Scientific). Cetuximab was obtained from the Clinic Pharmacy at MD Anderson 
Cancer Center. The secondary antibodies were purchased from Jackson 
ImmunoResearch Laboratories. For siRNA experiments, siRNA oligonucleotides 
targeting EGFR, ErbB2, and nonspecific siRNA control were purchased from Sigma. 
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The siRNA sequences were EGFR-siRNA-1: 5'-GACAUAGUCAGCAGUGACU-3'; 
EGFR-siRNA-2: 5'-GAUCUUUCCUUCUUAAAGA-3'; ErbB2-siRNA-1: 5'-
GCAGUUACCAGUGCCAAUA-3'; ErbB2-siRNA-2: 5'-
CAGAAUGGCUCAGUGACCU-3'.  
 
2.2 Constructs and stable transfectants 
For myc-His-tagged constructs, hRNase5 complementary DNA was subcloned 
into a pcDNA6/myc-His-A vector (Invitrogen). For GST-tagged constructs, bRNaseA 
and hRNase5 complementary DNAs were subcloned into a pGEX-6P-1 vector (GE 
Healthcare). The myc-GST-tagged hRNase5 was constructed by PCR from myc-
His-tagged hRNase5 with a C-terminal myc tag, and subcloned into a pGEX-6P-1 
vector. For HeLa stable transfectants, bRNaseA and hRNase5 complementary 
DNAs were subcloned into a modified pCDH-CMV-MCS-EF1-Puro vector (CD510B-
1, System Biosciences) containing a C-terminal Flag tag. Single-point mutants were 
generated by site-directed mutagenesis. For AsPC-1-hRNase5 stable transfectants, 
hRNase5 was subcloned into a pCDH-CMV-MCS-EF1-Puro vector. All stable 
transfectants were established by lentivirus infection and selected with puromycin. 
DyLight 594-bRNaseA was generated via fluorescent labeling of bRNaseA 
recombinant proteins with DyLight 594 dye.  
 
2.3 Cell culture 
Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM)/F12 or 
RPMI 1640 medium (for pancreatic cancer cell lines) supplemented with 10% fetal 
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bovine serum and antibiotics. Pancreatic cancer cell lines were kindly provided by 
Dr. Craig Logsdon (SW1990, SU.86.86) and Dr. Paul Chiao (CFPAC-1) at MD 
Anderson Cancer Center. In this series of experiments, cells were treated with 
bRNaseA and hRNase5 under serum-starved conditions for 24 h.  
 
2.4 Cell lysis, Western blot, and immunoprecipitation 
Cells were lysed in RIPA buffer (150 mM NaCl, 50 mM Tris [pH 7.5], 1% 
Nonidet P-40, and protease inhibitor mixture) and by sonication. Total lysates were 
collected after centrifugation at maximum speed and subjected to Western blot 
analysis with the indicated antibodies. For immunoprecipitation, cells after bRNaseA 
treatment were fixed with 1 mM dithiobis[succinimidylpropionate] (DSP, Thermo 
Scientific) at room temperature for 30 min, and the cell lysates were then 
immunoprecipitated with EGFR using an anti-EGFR and normal IgG antibodies as a 
negative control, followed by Western blot analysis with the indicated antibodies. 
 
2.5 Preparation of secreted proteins  
Cells were maintained in a serum-starved medium for 24 h, and media 
containing secreted proteins were collected. After filtration using 0.45 µm filters to 
remove cell debris, media were concentrated at 5,000×g for 1 h by Amicon Ultra-15 
Centrifugal Filter Units (UFC900324, Millipore) to a desired volume of secreted 
proteins. 
 
2.6 RNase activity detection assay 
  
24 
 
RNase activity was detected using Ambion® RNaseAlert® Lab Test kit 
(Invitrogen) with a slight modification. In brief, 5 µl of 10× RNaseAlert buffer was 
added to one tube of fluorescent substrate, and 45 µl of the test sample was then 
added to the tube. The mixture was sequentially pipetted into a well of a 96-well 
plate, and monitored at 37°C to collect real-time fluorescence data at 5 min intervals 
for the indicated time period using a BioTek Synergy™ Neo multi-mode reader. 
 
2.7 Confocal microscopy 
Confocal microscopy was performed as standard procedures described 
previously (Wang et al., 2010c). Cells were fixed in 4% paraformaldehyde for 15 
min, permeabilized with 0.5% Triton X-100 for 15 min, and blocked with 5% bovine 
serum albumin for 1 h. After the incubation with primary antibodies overnight at 4°C, 
cells were then further incubated with the appropriate secondary antibodies tagged 
with fluorescein isothiocyanate, Texas red, or Alexa 647 (Molecular Probes) for 1 h 
at room temperature. Nuclei were stained with DAPI contained in the mounting 
reagent (Invitrogen). Confocal fluorescence images were captured using a Zeiss 
LSM 710 laser microscope. Three-dimensional image was performed by Imaris 
software (Bitplane). In all cases, optical sections through the middle planes of the 
nuclei as determined using nuclear counterstaining were obtained. 
 
2.8 Duolink® in situ proximity ligation assay (PLA) 
Cells were fixed with 4% paraformaldehyde for 15 min, permeabilized with 0.5% 
Triton X-100 for 15 min, and blocked with 5% bovine serum albumin. Cells were 
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then incubated with mouse anti-EGFR antibody (1:2,000; Thermo Scientific) and 
rabbit anti-bRNaeseA (1:400; Abcam) or anti-flag antibody (1:200; Cell Signaling) 
for 30 min. The fluorescence signals were detected by the Duolink® in situ PLA 
probe (Axxora) according to the manufacturer’s instructions and visualized by using 
a Zeiss LSM 710 laser microscope. 
 
2.9 Cell migration and invasion assays  
Cell migration and invasion were performed using BioCoatTM Control Cell 
Culture Insertsin and BioCoatTM Growth Factor Reduced Matrigel Invasion 
Chambers (BD Biosciences), respectively. Culture medium containing 10% fetal 
bovine serum as a chemoattractant was added to the plate and cells (2.5×104 
cells/24-well chamber) in serum-free culture medium with the indicated treatments 
were added to the chamber. The chamber was then incubated at 37°C for 24 h (for 
HeLa cells) or 72 h (for AsPC-1 stable transfectants) to allow cells to penetrate an 8 
µm pore size, uncoated membrane or a Matrigel-coated membrane. Cells remained 
on the upper surface of the membrane were removed with a cotton swab, and those 
on the underside of the membrane were fixed with 4% paraformaldehyde, stained 
with 0.5% crystal violet, and microscopically counted from three random fields of 
each membrane. The average cell number per field for triplicate membranes was 
used to calculate the mean with SD. The values of cell migration and invasion are 
shown as number of migrated cells and invaded cells per field, respectively. The 
relative fold at empty vector without treatment or the first bar was defined as 1. 
 
  
26 
 
2.10 Detection of ligands-EGFR binding affinity by ELISA 
ELISA 96-well plates were captured with 3 µg/ml anti-EGFR antibody (Abcam) 
in 0.2 M sodium phosphate buffer (pH 6.5) at 100 µl/well overnight at room 
temperature. The plates were then rinsed three times with phosphate-buffered 
saline with 0.05% Tween-20 (PBST) and blocked with 200 µl/well of 1% BSA 
solution containing 0.05% Tween-20 at 37°C for 2 h. After rinsing three times with 
PBST, 100 µl/well of A431-RIPA lysates or RIPA buffer only as a negative control 
were added and incubated at 37°C for 1.5 h. The plates were then washed with 400 
µl/well of 1M sucrose three times, shaking 1 min per time, followed by addition of 
recombinant hRNase5, bRNaseA, or human biotin-EGF at a series of diluted 
concentrations in RIPA buffer. After incubation at 37°C for 1.5 h, wells were washed 
with 400 µl/well of 1M sucrose three times, shaking 1 min per time, and 100 µl/well 
of biotin-conjugated detection antibodies in blocking buffer was added for incubation 
at 37°C for 1 h. The plated were washed with 1M sucrose for three more times with 
shaking, and 100 µl/well of streptavidin-conjugated HRP (1:2,000 in blocking buffer) 
was added and incubated for 30 min at room temperature. The wells were washed 
again with 1M sucrose three times with shaking, and 100 µl/well of TMB as a 
peroxidase substrate were added and incubated for 30 min at room temperature. 
The reaction was terminated by addition of 50 µl/well of stop solution. The optical 
density was determined at 450 nm, corrected by subtraction of readings at 570 nm, 
using a BioTek Synergy™ Neo multi-mode reader. The dissociation constant (KD) 
and Bmax were estimated by the above binding data and then transformed to 
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create a Scatchard plot with GraphPad Prism program (version 6; Prism Software 
Inc., San Diego, USA). 
 
2.11 Patient plasma samples  
Total 40 patient plasma samples, collected as per protocols LAB01-526, 
LAB10-0434 (TexGen biorepository), and LAB05-0131, were obtained from 30 
patients with pancreatic adenocarcinoma, who were untreated previously 
(cancer/case group: 10 males and 20 females; mean age, 58.8 years; range, 37-77 
years) and 10 plasma samples from screening patients who do not have cancer 
(normal/control group: 3 males and 7 females; mean age, 51.0 years; range, 32-54 
years). Each patient provided informed consent at the time of plasma withdrawal. 
 
2.12 Tissue microarray  
Tissue microarray of 119 cases in pancreatic cancer were analyzed by 
immunohistochemistry staining using anti-phospho-EGFR-Tyr1068 (1:50, 3777, Cell 
Signaling) and anti-hRNase5 (1:50, AF265, R&D Systems) antibodies. 
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Chapter 3 
Bovine RNase A exhibits  
an EGFR ligand-like function              
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Background and Rationale 
Elevated levels of ribonuclease (RNase) have been reported years ago in the 
serum of pancreatic cancer patients (Reddi & Holland, 1976; Shimoyama et al., 
1996; Warshaw et al., 1980) and proposed to serve as a diagnostic marker for 
pancreatic cancer (Misek et al., 2007; Zhao et al., 1998). Human RNase 5 (also 
named angiogenin), which promotes malignancy through angiogenesis, was 
speculated to have an unidentified cell surface receptor (Hu et al., 1997). Bovine 
pancreatic RNase A (hereinafter referred to as bRNaseA), the first enzyme 
sequenced as a classic model system for protein structure and enzymatic function 
(Raines, 1998), is a secreted endoribonuclease commonly used in research to 
remove RNAs (Benito et al., 2008; Cuchillo et al., 2011; Findlay et al., 1961; 
Marshall et al., 2008). One of the most well-characterized cell surface receptors, the 
epidermal growth factor receptor tyrosine kinase (EGFR-RTK), is a target of many 
cancer therapies. RNases and RTKs from two unrelated superfamilies are 
associated with distinct functions but they may share a common role in signal 
transduction as extracellular RNAs (eRNAs) have recently been discovered to act 
as signaling molecules and even serve as therapeutic biomarkers (Dinger et al., 
2008; Fischer et al., 2013).  
In an attempt to study how eRNAs might affect cell signaling, which is not fully 
understood, we unexpectedly discovered that bovine RNase A and its human 
equivalent, RNase 5/angiogenin, function as unique EGFR ligands and that serum 
RNase 5 may contribute to resistance to EGFR targeted therapy, cetuximab. 
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Results 
3.1 Bovine RNase A promotes oncogenic transformed phenotypes 
To study how eRNAs affect cellular processes and determine their potential 
clinical significance, we designed a pilot test by treating cells with a recombinant 
bRNaseA protein to broadly degrade eRNAs. The catalytic activity of bRNaseA was 
validated by RNase activity detection assay (Figure 3-1A) and sucrose gradient 
fractionation using p68 RNA helicase as a positive control (Sytnikova et al., 2011) 
(Figure 3-1B). Interestingly, we found that bRNaseA triggered oncogenic 
transformed phenotypes. Specifically, bRNaseA induced epithelial-mesenchymal 
transition (EMT)-like morphological changes in different cancer types (Figure 3-2) 
accompanied by changes in EMT markers, including decreased expression of E-
cadherin and enhanced expression of mesenchymal markers Vimentin, ZEB-1, Slug, 
and Snail (Figure 3-3). Cells treated with bRNaseA also showed enhanced cell 
mobility (Figure 3-4) and cell migration and invasion in a dose-dependent manner 
(Figure 3-5), except for cell growth (Figure 3-6). These results suggest that 
bRNaseA induces EMT. 
 
3.2 Extracellular RNA is not involved in bovine RNase A-triggered EMT 
To further determine whether eRNAs are involved in bRNaseA-triggered EMT, 
we tested if the catalytic enzyme-deficient mutant of bRNaseA can still induce EMT. 
To this end, we generated a GST-tagged wild-type bRNaseA (GST-bRNaseA-WT) 
and a catalytic-deficient mutant (GST-bRNaseA-H119A) bearing a single mutation 
at His119 (Zegers et al., 1994) (Figure 3-7A). Surprisingly, a comparison between 
  
 
 
Figure 3-1. bRNaseA harbors endoribonuclease enzyme activity. 
(A) Detection of bRNaseA enzyme activity, at 50 pg/ml, using an RNaseAlert
Test kit monitored by a real
helicase, a RNA binding protein as a p
bottom) sucrose gradients.
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Figure 3-2. Treatment of bRNaseA triggers EMT
(A and C) Cell morphological change of four pancreatic cell lines, and a lung (H226) 
and ovarian ( SkOV3) cancer 
morphological change of HeLa cells treated with bRNaseA in a dose
manner for 1 day.  
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Figure 3-3. Treatment of bRNaseA modulates molecular EMT makers.
AsPC-1 (A), Panc-1 (B), and HeLa cells (
time points and lysates were subjected to Western blot analysis with the indicated 
antibodies (EMT markers).
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Figure 3-4. bRNaseA enhances cell mobility in a wound
The distance of the wound gaps at the indicated time points determined using the 
ImageJ software program (version 1.38x; National Institutes of Health) and 
normalized against the width at time 0 was plotted diagrammatically as shown in the 
lower panel. Error bars represent SD from three independent experiments. 
Statistical analysis was performed by Student’s 
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P < 0.01.  
  
 
 
 
 
Figure 3-5. bRNaseA triggers cell migration and invasion in a dose
manner.  
Mgration assay in transwells and invasion assay in matrigel
chambers of HeLa cells. Top, representative images shown. Bottom, quantification 
of cell migration and invasion
was performed by Student’s 
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. Error bars represent SD. n = 3. Statistical analysis 
t test. *, P < 0.05; **, P < 0.01.  
 
-dependent 
  
 
 
 
Figure 3-6. The effect of bRNaseA on cell proliferation. 
Cell numbers were measured by a Coulter
different cell lines. Error bars represent SD. 
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Figure 3-7. Extracellular RNA is not involved in bRNaseA
(A) Coomassie blue staining of bacterial
GST-bRNaseA-WT and GST
recombinant bRNaseA. 
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cells treated with GST-bRNaseA-WT and those treated with GST-bRNaseA-H119A 
revealed similar morphological changes (Figure 3-7B) and expression levels of 
ZEB-1 (Figure 3-7C), suggesting that the catalytic activity of bRNaseA is not 
required. The enzymatic activity of GST-bRNaseA-H119A was abolished as 
indicated by RNase activity detection assay (Figure 3-7D). Together, these data 
indicate that bRNaseA itself but not the degradation of eRNAs induces EMT (see 
more details in Chapter 5). 
 
3.3 Bovine RNase A triggers signaling cascades of tyrosine-phosphorylation  
Since bRNaseA can enter cells (Chao & Raines, 2011), we suspected that the 
internalized bRNaseA may play a role in EMT induction. Indeed, increased uptake 
of bRNaseA (signified by red color) was readily detectable without significant 
changes in the intracellular RNA levels as indicated by SYTO green fluorescence 
staining (Figure 3-8).  
Tyrosine kinase cascades have been shown to associate with EMT (Hardy et 
al., 2010; Huber et al., 2005), and thus we asked whether bRNaseA might induce   
EMT by activating the tyrosine kinase cascades. To this end, we examined the 
phospho-tyrosine (p-Tyr) profile in the presence of bRNaseA treatment in cellular 
lysates by blotting with a p-Tyr antibody. Interestingly, we found that bRNaseA 
triggered signaling cascades of tyrosine phosphorylation in multiple types of cancer 
cells (Figure 3-9). Notably, the p-Tyr content corresponding to the RTK-equivalent 
molecular weight was substantially increased by bRNaseA treatment (170 to 200-
kDa).  
  
 
 
Figure 3-7. Extracellular RNA is not involved in bRNaseA
(B) Cell morphological change of HeLa cells treated with GST
bRNaseA-WT, and GST-bRNaseA
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-triggered EMT.
-H119A for 3 days. (C) Cell lysates from (B) were 
  
-vector, GST-
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subjected to Western blot analysis with the antibody against the EMT marker, ZEB-
1. Tubulin served as loading control. (D) Detection of RNase enzyme activity in 
GST-vector, GST-bRNaseA-WT, and GST-bRNaseA-H119A using an RNaseAlert® 
Lab Test kit monitored by a real-time fluorimeter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 3-8. bRNaseA internalizes into cells with no interference of 
RNA level.  
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Confocal microscopy of RNA level staining with SYTO® RNASelect™ green-
fluorescent cell stain and bRNaseA using an anti-bRNaseA antibody (red signals) 
for a 30-min treatment of bRNaseA in human cervical HeLa (A), pancreatic cancer 
AsPC-1 (B), and bovine kidney MDBK (C) cells. Nuclei were stained with DAPI. Bar, 
5 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 3-9. bRNaseA triggers signaling cascades of tyrosine
(A) HeLa, (B) pancreatic
bovine kidney cells were treated with or without bRNaseA, and lysates were 
subjected to Western blot analysis with a phospho
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-phosphorylation.
, (C) breast, ovarian, lung cancer cells as well
-tyrosine (p-Tyr) antibody. 
 
 
 as (D) 
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 3.4 EGFR-RTK is the primary target of bovine RNase A  
We then performed a non-biased antibody array for human phospho-RTKs to 
determine which RTK(s) might be the target(s) of bRNaseA. Among 49 RTKs in the 
array, only EGFR and ErbB2 had increased phosphorylation after bRNaseA 
treatment in both cervical (HeLa) and pancreatic (AsPC-1) cancer cells (Figure 3-
10). We further validated the results using the phospho-tyrosine antibodies specific 
for EGFR and ErbB2 and found that most tyrosine phosphorylation peaked at 5 min 
after bRNaseA treatment (Figure 3-11), a phenomenon similar to EGFR ligand 
stimulation (Avraham & Yarden, 2011). To further address which of these two RTKs 
is required for bRNaseA-dependent tyrosine phosphorylation, we knocked down 
EGFR and ErbB2 by small interfering RNAs (siRNAs). Silencing EGFR attenuated 
ErbB2 tyrosine phosphorylation without affecting ErbB2 expression, but not vice 
versa (Figure 3-12A). We also observed similar results in EGFR-knockdown stable 
cells expressing small hairpin RNA (shRNA) targeting EGFR (Figure 3-12B). 
Together, these results suggest that ErbB2 tyrosine phosphorylation induced by 
bRNaseA is dependent on EGFR. Interestingly, in MDA-MB-453 breast cancer cells 
that do not express endogenous EGFR, bRNaseA treatment had no effect on pan-
tyrosine phosphorylation (Figure 3-12C), which strongly suggests that EGFR, but 
not ErbB2, is the predominant target of bRNaseA. 
 
 
  
 
 
 
Figure 3-10. EGFR and ErbB2 show increased phosphorylation after bRNaseA 
treatment in human phospho
HeLa and AsPC-1 cells were treated with or without bRNase A,
subjected to human phospho
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-RTK antibody array. 
 and lysates were 
-RTK antibody array analysis. 
  
 
 
Figure 3-11. bRNaseA treatment activates EGFR and ErbB2
HeLa (A) and AsPC-1 (B
and lysates were subjected to Western blot analysis with the indicated antibodies. 
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) cells were treated with bRNaseA at different time points, 
 
  
 
 
 
Figure 3-12. ErbB2 tyrosine phosphorylation induced by bRNaseA is EGFR 
kinase-dependent. 
 (A) Western blot analysis of lysates from HeLa cells transfected with the individual 
siRNAs against EGFR and ErbB2 in the presence or absence of bRNaseA. 
 
 
 
47 
 
  
 
Figure 3-12. ErbB2 tyrosine phosphorylation induced by bRNaseA is EGFR 
kinase-dependent.  
(B) Western blot analysis of lysates of HeLa EGFR
(EGFR-A and EGFR-B) in the presence or absence of bRNaseA. (
and SKBR3 cells were treated with or without bRNaseA, and lysates
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3.5 Bovine RNase A activates EGFR downstream signaling pathways 
To further pursue whether bRNaseA activates the downstream signaling 
cascades of EGFR, another antibody array for human phospho-kinases was 
performed. The results showed that six serine and threonine signaling pathways, 
including p38α, ERK1/2, Gsk-3α/β, Akt, CREB, and RSK1/2/3, were commonly 
phosphorylated in two cells after bRNaseA treatment (Figure 3-13), in which some 
candidates, such as ERK1/2 and Akt pathways, were confirmed using the indicated 
antibodies (Figure 3-14). Pretreating these cells with small-molecular tyrosine-
kinase inhibitors (TKIs) targeting EGFR (gefitinib and AG1478) blocked the 
bRNaseA-triggered EGFR, and subsequently Akt and ERK, activation (Figure 3-15). 
These results indicate that bRNaseA triggers EGFR-downstream signaling in an 
EGFR kinase-dependent manner.  
 
3.6 Bovine RNase A associates with EGFR in vivo and in vitro  
Since bRNaseA stimulates tyrosine phosphorylation of EGFR and its 
downstream signaling, we asked whether bRNaseA functions as an EGFR ligand. 
To this end, we first validated the association between EGFR and bRNaseA by 
multiple methods, including in vivo co-immunoprecipitation, in vitro binding assay, 
confocal microscopy, and Duolink in situ proximity ligation assay (PLA). bRNaseA 
co-immunoprecipitated with EGFR using an anti-EGFR antibody in vivo (Figure 3-
16A), and the interaction was primarily through the extracellular domain (ECD) of 
EGFR (Figure 3-16B). In addition, bRNaseA interacted with the N-terminal EGFR 
recombinant protein (N-EGFR-Fc) that contained only the extracellular ligand- 
  
 
 
 
 
Figure 3-13. bRNaseA activates EGFR downstream signaling pathways 
human phospho-kinase antibody array.
HeLa and AsPC-1 cells were treated with or without bRNase A, and lysates were 
subjected to human phospho
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-kinase antibody array analysis. 
in a 
  
 
 
 
Figure 3-14. bRNaseA treatment activates ERK and Akt. 
HeLa (A) and AsPC-1 (B
and lysates were subjected to Western blot analysis 
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) cells were treated with bRNaseA at different time points, 
with the indicated antibodies. 
  
 
 
 
 
 
 
 
 
Figure 3-15. EGFR-TKIs blocks bRNaseA
HeLa cells were pretreated with EGFR
bRNaseA treatment, and lysates were subjected to Western blot analysis with the 
indicated antibodies. 
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-triggered EGFR signaling
-TKIs (gefitinib and AG1478), followed by 
.  
  
 
 
 
 
Figure 3-16. bRNaseA associates with EGFR
(A) HeLa cells underwent immuneprecipitation with antibodies targeting EGFR or 
normal IgG. Precipitates were analyzed by Western blot the indicated antibodies. 
The right panel shows the input lysates. (
293T cells transfected with myc
extracellular domain (ECD), and intracellular domain (ICD) plasmids,
using His beads. 
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B) In vivo binding assay of bRNaseA in 
-His-tagged EGFR containing full-length (FL), 
 pulled down 
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binding domain in vitro (Figure 3-16C). Consistent with the biochemical studies, we 
observed co-localization of EGFR and bRNaseA using confocal 
immunofluorescence assay as indicated by yellow signals in the merged image 
(Figure 3-17A), which was further validated by examining sequential photosections 
of a cell in multiple layers in three-dimensions (Figure 3-17B). This EGFR/bRNaseA 
association (indicated by yellow merged signals) was also detected by a non-
antibody-based approach using bRNaseA recombinant proteins labeled with 
DyLight 594 dye that generated red fluorescence for confocal analysis (Figure 3-18). 
In addition, a new and more sensitive Duolink in situ PLA technology, which utilizes 
detectable DNA molecules amplified by binding of two protein-DNA conjugates in 
close proximity (Fredriksson et al., 2002), demonstrated a number of interactions 
between EGFR and bRNaseA (Figure 3-19). These results from these assays 
support the bRNaseA/EGFR association both in vitro and in vivo.  
 
3.7 Bovine RNase A acts as an EGFR ligand to convey intracellular EGFR 
signaling 
We further found that cetuximab, a monoclonal EGFR antibody that blocks 
binding of ligands to EGFR, inhibited bRNaseA-induced activation of EGFR and its 
downstream Akt signaling (Figure 3-20). Disrupting the interaction between the N-
terminal ligand-binding domain of EGFR and bRNaseA by competition with an N-
EGFR-Fc recombinant protein or EGFR-ECD also decreased EGFR activation 
triggered by bRNaseA (Figure 3-21). Collectively, the results suggest an 
unrecognized role of bRNaseA as an EGFR ligand to convey EGFR signaling. 
  
 
 
 
 
 
 
 
 
Figure 3-16. bRNaseA associates with EGFR
 (C) In vitro binding assay of bRNaseA and N
recombinant protein, pulled down using protein G beads. Normal IgG and BSA 
served as negative controls.
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terminal EGFR 
  
 
Figure 3-17. bRNaseA co
immunofluorescence assay
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(A) Confocal microscopy of HeLa cells stained with DAPI (blue), anti-bRNaseA 
(green), and anti-EGFR (red) antibodies. Boxed areas are shown in detail in the 
insets. Bar, 5 µm. (B) A single HeLa cell was dissected into 32 focal sections with a 
thickness of 0.5 µm each. The nucleus spanned between focal plans 04-12. Co-
localization of EGFR and bRNaseA, as indicated by the yellow signals in the 
merged images, is shown from plans 06-10 in the insets (white arrows). Boxed 
areas are shown in detail in the insets. Bar, 5 µm. 
 
 
 
 
 
 
 
 
 
  
Figure 3-18. DyLight 594
 (A) Confocal microscopy of HeLa cells stained with DAPI (blue), DyLight 594
labeled bRNaseA (red), and 
shown in detail in the insets. Bar, 5 
shown in Inset 1 of (A). 
 
58 
 
-labeled bRNaseA co-localizes with EGFR
an anti-EGFR antibody (green). Boxed areas are 
µm. (B) Intensity profile of two yellow signals 
.  
-
  
 
 
Figure 3-19. bRNaseA 
technology.  
Detection of EGFR and bRNaseA interaction by Duolink in situ PLA technology. 
HeLa cells were stained with EGFR and bRNaseA antibodies. The number of 
interactions per cell is shown on the right. Error bars represent SD. n = 3.
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interacts with EGFR using Duolink in situ PLA 
 
 
 
  
Figure 3-20. Cetuximab attenuates bRNaseA
its downstream Akt signaling. 
HeLa cells were pretreated with cetuximab (10 µg/ml) at 4°C for 1 h, followed by 
bRNaseA stimulation for 5 min, and lysates were subjected to Western blot analysis 
with the indicated antibodies.
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-induced activation of EGFR and 
 
 
 
 
 
  
Figure 3-21. Blockage of the association between EGFR and bRNaseA inhibits 
bRNaseA-induced EGFR signaling.
(A) HeLa cells were treated with bRNaseA pre
Fc, as indicated, and lysates were 
antibodies. (B) HeLa cells transfected with the extracellular domain of EGFR 
(EGFR-ECD) were treated with bRNaseA treatment, and lysates were subjected to 
Western blotting with the indicated antibodies.
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Chapter 4 
Human RNase 5 serves  
as an EGFR ligand 
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Background and Rationale 
The human RNase A superfamily consists of 13 members and all are secretory 
proteins (Cho et al., 2005). In addition to their catalytic activities against specific 
RNAs, they possess a number of physiological functions, e.g., digestion of dietary 
RNA (RNase 1), angiogenesis (RNase 5/angiogenin; hereinafter referred to as 
hRNase5), and antiviral host defense (RNases 2, 3, 7) (Li & Hu, 2012; Rosenberg, 
2008; Sorrentino, 2010). Among them, human pancreatic RNase 1 and hRNase5 
are most evolutionarily closely related to bRNaseA (Peracaula et al., 2000; 
Rosenberg, 2008). We next investigated whether the newly discovered function of 
bRNaseA, which acts as an EGFR ligand and promotes transformed phenotypes, 
also exists in human RNase A members. 
 
Results 
4.1 Human RNase 5 is predominantly secreted in pancreatic cancers 
We examined the levels of secreted hRNase5 and RNase 1 in a panel of 10 
pancreatic cancer cells and found all cell lines secreted hRNase5 whereas only one 
cell line (Capan-1) secreted RNase 1 (Figure 4-1), suggesting that hRNase5 is the 
RNase predominantly expressed in pancreatic cancers. Furthermore, we analyzed 
the correlation of EGFR with ANG (gene encoding hRNase5 protein) and RNASE1 
in pancreatic ductal adenocarcinoma using the cancer microarray database 
ONCOMINE (Rhodes et al., 2004). EGFR correlated positively with ANG1 (P < 
0.0001) (Figure 4-2) but not RNASE1.  
 
  
 
 
 
 
 
 
Figure 4-1. hRNase5 is secreted in a panel of 10 pancreatic cancer cells.
Analysis of the expression level of hRNase5 and RNase 1 proteins secreted in 
pancreatic cancer cells. 
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Figure 4-2. hRNase5 correlat
adenocarcinoma. 
Heat map analysis of EGFR
(PDAC) via a cancer microarray database, ONCOMINE, plotted diagrammatically in 
the lower panel. n = 87. 
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4.2 Human RNase 5 functions as an EGFR ligand to activate EGFR signaling 
We then investigated whether hRNase5 also functions as an EGFR ligand. 
Indeed, similar to bRNaseA, hRNase5 bound to the N-terminal domain of EGFR 
directly (Figure 4-3A), which was attenuated by pretreatment of cetuximab (Figure 
4-3B, lane 3 vs. lane 4). In addition, hRNase5 also activated EGFR and its 
downstream targets in a dose-dependent manner (Figure 4-4). These hRNase5-
mediated EGFR activations were blocked by pretreatment of cetuximab (Figure 4-5) 
and EGFR-TKIs (Figure 4-6), further supporting that like bRNaseA, hRNase5 also 
functions as an EGFR ligand to convey intracellular signaling by binding to the 
extracellular ligand-binding domain of EGFR.  
 
4.3 Human RNase 5 triggers cell migration and invasion through the binding 
to and activating EGFR 
To determine whether EGFR is required for hRNase5-triggered oncogenic 
functions in pancreatic cancers, we generated AsPC-1 stable transfectants that 
express hRNase5 (designated as AsPC-1-hRNase5; Figures 4-7A and 4-7B) at a 
level comparable to CFPAC-1 cells that express high levels of hRNase5 (Figure 4-
7C) and performed cell migration and invasion assays. Compared with vector 
control, hRNase5-expressing stable cells exhibited enhanced cell migration and 
invasion (Figures 4-8A and 4-8B), but these effects were significantly repressed by 
pretreating cells with cetuximab, EGFR-TKIs, or hRNase5 neutralizing antibody 
(ANG Ab). These results support the notion that hRNase5 triggers pancreatic 
cancer cell migration and invasion via binding to and activating EGFR. 
  
 
Figure 4-3. Cetuximab attenuates 
EGFR.  
(A) Left: in vitro binding assay of 
hRNase5) and N-EGFR-Fc, pulled down using protein G beads. 
(GST) alone is a negative 
N-EGFR-Fc, which was pre
binding and expression of GST
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a GST-tagged plasmid expressing hRNase5 (GST
A
control. (B) In vitro binding assay of GST
-incubated with cetuximab. An asterisk represents 
-hRNase5. 
 
-
n empty vector 
-hRNase5 and 
  
 
 
 
 
 
Figure 4-4. hRNase5 treatment activates EGFR and the downstream signaling 
pathways.  
HeLa cells were treated with increasing concentrations of hRNase5 for 5 min and 
lysates were subjected to Western blotting with the indicated antibodies.
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Figure 4-5. Cetuximab attenuates 
downstream Akt signaling. 
HeLa cells were pretreated with cetuximab (10 µg/ml) at 4°C for 1 h, followed by 
hRNase5 stimulation for 5 min, and lysates were subjected to Western blot analysis 
with the indicated antibodies.
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hRNase5-induced activation of EGFR and its 
 
 
  
 
 
Figure 4-6. Pretreatment of
activation.  
AsPC-1 (A), Panc-1 (B), and HeLa (
(erlotinib or gefitinib), followed by hRNase5 treatment for 5 
subjected to Western blotting with the indicated antibodies.
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 EGFR-TKIs inhibits hRNase5-mediated EGFR 
C) cells were pretreated with EGFR
min, and lysates were 
 
-TKIs 
  
 
 
 
 
Figure 4-7. The levels of hRNase5 in AsPC
comparable to those in highly
(A) Western blot analysis of secreted 
expressing hRNase5 (AsPC
comparison of hRNase5 expression level in AsPC
to increasing amounts of recombinant hRNase5 proteins (
cancer cell lines (C). 
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-expressed cells.  
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-1-hRNase5) and empty vector (AsPC
-1-hRNase5 and AsPC
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-1-vector). A 
-1-vector, 
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Figure 4-8. hRNase5 triggers cell migration and invasion through the binding 
to and activating EGFR. 
(A) Representative images of cell migration and invasion assays of AsPC
transfectants expressing hRNase5 t
EGFR-TKI (gefitinib), or hRNase5 neut
Quantification of cell migration and invasion from (A
Statistical analysis was performed by Student’s t te
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reated with an EGFR antibody (cetuximab), an 
ralization antibody (ANG Ab). (
). Error bars represent SD. n = 3. 
st. **, P < 0.01; ***, P < 0.001. 
-1 stable 
B) 
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4.4 The expression level of human RNase 5 is significantly elevated in 
pancreatic cancer patients 
Decades ago, investigators reported that the activities of serum RNases (Reddi 
& Holland, 1976; Warshaw et al., 1980), and later the expression of hRNase5 
(Shimoyama et al., 1996) were elevated in pancreatic cancer patients and 
suggested that RNases could serve as diagnostic markers in pancreatic cancer 
progression (Misek et al., 2007; Zhao et al., 1998). We re-evalulated the 
concentration of RNase 1 and hRNase5 in the plasma samples of pancreatic cancer 
patients for comparison with non-cancer control group (Figure 4-9). Consistent with 
the previous report (Shimoyama et al., 1996), a significant increase in plasma 
hRNase5 was indeed detected in the cancer group (P = 0.014; Figure 4-9A) 
whereas  the mean concentrations of plasma RNase 1 between these two groups 
were not significant (P = 0.83; Figure 4-9B).  
Interestingly, there were no significant differences in traditional EGFR ligands, 
EGF and TGF-α, between normal and pancreatic cancer patient samples (Figures 
4-9C and 9D); their mean concentrations in patients were approximately 20,000-fold 
lower than that of plasma hRNase5 (18.1 and 15.6 pg/ml vs. 458.8 ng/ml; Table 4-
1).  
 
 
  
 
 
Figure 4-9. Human RNase 5 is elevated in plasma samples of pancreatic 
cancer patients.  
Analysis of hRNase5 (A), human RNase 1 (
samples of pancreatic cancer 
by an enzyme-linked immunosorbent assay (R&D Systems).
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B), EGF (C), and TGF-α
patients for comparison with non-cancer control group 
 
 (D) in plasma 
  
 
 
 
 
 
 
Table 4-1. Analysis of hRNase5, human RNase 1, EGF, and TGF
samples of pancreatic cancer patients for comparison with 
control group by ELISA.
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-α in plasma 
non-cancer 
  
4.5 A physiological relevance between activated EGFR and 
pancreatic cancers 
Importantly, human pancreatic tumor tissue microarrays showed that phospho
EGFR-Y1068, which is indicative of EGFR 
hRNase5 expression (P 
association between activated EGFR and hRNase5 in pancreatic cancers.
 
Figure 4-10. hRNase5 correlates 
human pancreatic tissue microarrays
Pancreatic cancer tissue microarray analysis for the correlation between hRNase5 
and phospho-EGFR-Y1068.
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activation, was positively correlated with 
= 0.03; Figure 4-10), strongly suggesting a physiological 
positively with activated EGFR expression in 
.  
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Chapter 5 
The EGFR ligand-like activity  
of pancreatic RNase is  
independent of its enzyme activity 
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Background and Rationale 
RNase is well known to associate with intrinsic catalytic enzyme activities to 
degrade RNA (Cuchillo et al., 2011; Marshall et al., 2008); however, as previously 
mentioned, bRNaseA induced EMT via a catalytic-independent pathway (Figure 3-
7). Next, we asked whether hRNase5 and bRNaseA bind to EGFR and activate 
EGFR signaling pathways, such as Akt and ERK, in a catalytic-independent 
pathway. 
 
Results 
5.1 RNase enzyme activity is not required for tyrosine-phosphorylation 
cascades triggered by GST-bRNaseA 
In addition to an enzymatic activity-independent role of bRNaseA in EMT 
process, the increased p-Tyr profile and EGFR activation were also observed in the 
cells treated with enzyme-deficient GST-bRNaseA-H119A mutant, at a similar level 
compared to that with GST-bRNaseA-WT (Figure 5-1), suggesting that bRNaseA-
triggered tyrosine-phosphorylation cascades were independent of its catalytic 
enzyme activity. 
 
5.2 RNases activate and bind to EGFR independently of their catalytic enzyme 
activities 
Thus, we then asked whether the enzyme activities of bRNaseA and hRNase5 
expressed in mammalian cells were also independent of EGFR binding in addition 
to the activation. To this end, we generated wild-type and catalytic enzyme-deficient  
  
 
 
 
 
Figure 5-1. bRNaseA-triggered tyrosine
activation is independent of its catalytic 
HeLa cells were treated with PBS only, GST
bRNaseA-H119A for 5 min, and lysates were subjected to Western blot analysis 
with the indicated antibodies. 
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mutants of bRNaseA and hRNase5, either by transient transfection or stably 
expression in HeLa cells. Media from HeLa cells transiently transfected with empty 
vector or Flag-bRNaseA plasmids expressing wild-type (Flag-bRNaseA-WT) or 
catalytic-deficient bRNaseA mutant (Flag-bRNaseA-H119A) were collected and 
concentrated to evaluate the RNase activities. As shown in Figure 5-2A, RNase 
activities were abolished in cells expressing the Flag-bRNaseA-H119A mutant but 
not in those expressing Flag-bRNaseA-WT as indicated by the loss of fluorescence. 
Western blot analysis demonstrated that their expression levels were not affected 
(Figure 5-2B). We found that the secreted bRNaseA-H119A mutant lacking RNase 
activity still activated EGFR and the downstream ERK and Akt pathways at levels 
similar to bRNaseA-WT (Figure 5-2C). In addition, the lack of RNase activity in the 
catalytic-deficient mutant did not affect its interaction with EGFR (Figure 5-2D), and 
these results were validated in stable transfectants (Figure 5-3). 
A similar experiment was performed to test the catalytic-deficient mutants of 
hRNase5 (K40A and H114A; Figure 5-4A) with results indicating that hRNase5 
triggered EGFR phosphorylation (Figure 5-4B) and interacted with EGFR (Figure 5-
4C). Together, these findings indicate that human RNase 5 and bovine RNase A 
bind to EGFR and activate EGFR signaling pathways, without requiring their 
catalytic activities. 
 
 
 
  
Figure 5-2. bRNaseA activate
catalytic activities.  
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(A) Detection of RNase enzyme activity in concentrated culture media collected 
from cells transfected with Flag-bRNaseA-WT, Flag-bRNaseA-H119A, or empty 
vector, by using an RNaseAlert® Lab Test kit and monitored by a real-time 
fluorimeter. (B) Western blot analysis of secreted proteins in the media from HeLa 
cells expressing Flag-bRNaseA-WT, Flag-bRNaseA-H119A, or empty vector. The 
relative density at Flag-bRNaseA-WT was defined as 1 using the imageJ software 
program (version 1.38x; National Institutes of Health) to quantify the signals. (C) 
Left: HeLa cells were treated with culture media containing secreted proteins, as 
indicated in (B), for 5 min and lysates were subjected to Western blotting with the 
indicated antibodies. Right: the quantified signal representing the fold of EGFR 
phosphorylation against the amounts of the indicated secreted proteins. Error bars 
represent SD. n = 3. Statistical analysis was performed by Student’s t test. NS, P > 
0.05, not significant. (D) Detection of EGFR and bRNaseA interaction by Duolink in 
situ PLA technology. HeLa cells were treated with the secreted proteins, as 
indicated in (B), for 15 min, and fixed and stained with anti-EGFR and anti-
bRNaseA antibodies. The number of interaction per cell normalized to the amount 
of the secreted proteins is shown right. Error bars represent SD. n = 3. Statistical 
analysis was performed by Student’s t test. NS, P > 0.05, not significant. 
 
 
 
  
 
Figure 5-3. bRNaseA secreted in stable transfectants binds to EGFR 
independently of its catalytic activity. 
(A) Detection of RNase enzyme activity in the concentrated media of HeLa stable 
transfectants expressing Flag
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H119A, and empty vector, using an RNaseAlert® Lab Test kit monitored by a real-
time fluorimeter. (B) Western blot analysis of secreted proteins in HeLa stable 
transfectants expressing Flag-bRNaseA-WT, Flag-bRNaseA-K41A, Flag-bRNaseA-
H119A, and empty vector. The relative density at Flag-bRNaseA-WT was defined 
as 1 using the imageJ software program (version 1.38x; National Institutes of Health) 
to quantify the signals. (C) Detection of EGFR and bRNaseA interaction by Duolink 
in situ PLA technology. HeLa cells were treated with secreted WT, K41A, or H119A 
bRNaseA for 15 min as described in (B) and fixed and stained with anti-EGFR and 
anti-Flag antibodies. The number of interaction per cell normalized to the amount of 
the secreted proteins is shown on the right. Error bars represent SD. n = 3. 
Statistical analysis was performed by Student’s t test. NS, P > 0.05, not significant. 
  
  
 
Figure 5-4. hRNase5 secreted in stable transfectants 
EGFR independently of its catalytic activity. 
(A) Western blot analysis of hRNase5 in the culture media of HeLa stable 
transfectants expressing Flag
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H114A, or empty vector. The relative density at Flag-hRNase5-WT was defined as 
1 using the ImageJ software program (version 1.38x; National Institutes of Health) 
to quantify the signals. (B) Left: HeLa cells were treated with secreted WT, K40A, or 
H114A hRNase5 as described in (A) for 5 min and lysates were subjected to 
Western blot analysis with the indicated antibodies. Right: quantitation of the fold of 
EGFR phosphorylation against the amount of the indicated secreted proteins. Error 
bars represent SD. n = 2. Statistical analysis was performed by Student’s t test. NS, 
P > 0.05, not significant. (E) Detection of EGFR and hRNase5 interaction by 
Duolink in situ PLA technology. HeLa cells were treated with secreted WT, K40A, or 
H114A hRNase5 for 15 min as described in (A) and fixed and stained with anti-
EGFR and anti-Flag antibodies. The number of interaction per cell normalized to the 
amount of the secreted proteins is shown on the right. Error bars represent SD. n = 
3.  
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Chapter 6 
Characterization of interaction  
between EGFR and RNases 
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Background and Rationale 
The EGFR ligand-like activity of hRNase5 prompted us to ask whether 
hRNase5 share sequence homology with traditional EGFR ligands, such as EGF 
and heparin-binding EGF-like growth factor (HB-EGF). 
 
Results 
6.1 The C-terminal hRNase5 possesses highly and evolutionally conserved 
residuals with those on EGF and HB-EGF 
Primary sequence alignment showed that the C-terminal region (known for 
EGFR binding in EGF and HB-EGF) of hRNase5, EGF, and HB-EGF are highly and 
evolutionally conserved in different species (shown in red; Figure 6-1).  
 
6.2 The C-terminal domain of hRNase5 (amino acid 74-123) is required for 
EGFR binding  
To further study whether the C-terminal region of hRNase5 plays a role in 
binding to EGFR, we generated wild-type (WT), N- (∆N), and C-terminal deletion 
(∆C) constructs of hRNase5 and in vitro binding assay was performed. Consistent 
with the analysis in Figure 6-1, we did not detect any association with EGFR when 
this C-terminal region (amino acid 74-123) was deleted from hRNase5 (Figures 6-
2A and 6-2B), suggesting that this region is required for EGFR binding.  
 
 
 
  
 
Figure 6-1. Sequence alignment of RNase5 to known EGFR ligands (EGF and 
HB-EGF) in different species
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T-coffee sequence alignment (Notredame et al., 2000; Taly et al., 2011) of EGF, 
HB-EGF, and RNase 5 between human, mouse, and horse. Regions in red indicate 
high consistency, orange/yellow as an average consistency, and green/blue as the 
lowest consistency. Asterisks represent 100% conservation in all sequences; colons 
and dots represent partial sequence conservation.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 6-2. The C-terminal 
(A) A schematic diagram showing wild
(∆C) constructs of hRNase5. The numbers represent amino acid residues. NLS, 
nuclear localization signal. (B) 
hRNase5 WT and two of
hRNase5 ∆C, pulled down using protein G beads.
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hRNase5 is required for EGFR binding. 
-type (WT), N- (∆N), and C-terminal deletion 
In vitro binding assay of N-EGFR
 its deletion mutants, GST-hRNase5 ∆
 
 
-Fc with GST-
N and GST-
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6.3 Gln93 and Tyr94 within C-terminal region of human RNase 5 are critical for 
efficient binding to EGFR 
To map the potential EGFR binding site(s) in hRNase5, we compared the C-
terminal region between human EGF, hRNase5, and several hRNase5 homologues 
and found that they are indeed highly conserved (Figures 6-3A and 6-3B).  
We identified four conserved residues, including two Cys (C81 and C92), which 
are generally crucial for protein structure, and Gln (Q93) and Tyr (Y94) that 
correspond to the side chains in human EGF reported to bind to EGFR (Figure 6-4A) 
(Li et al., 2005), and when mutated to alanine, their association with EGFR was 
inhibited (Figure 6-4B), suggesting that they may play a role in binding of hRNase5 
to EGFR.  
The decrease binding of hRNase5-Q93A to EGFR was further validated in vivo 
by incubating N-EGFR-Fc with the collected media containing secreted WT and 
Q93A mutant of hRNase5 following transfection (Figures 6-5A and 6-5B). 
Interestingly, Y94 hRNase5 mutant was not detected in the media after transfection 
as the mutation may have affected its secretion (Figure 6-5B). Similarly, no 
interaction was detectable between EGFR and hRNase5 containing the Cys 
mutants to alanine, likely due to lack of protein secretion in the media (Figure 6-6). 
Together, results from the in vitro assays suggest that Q93 and Y94 within C-
terminal region of hRNase5 are required for efficient binding to EGFR. 
 
 
 
  
 
Figure 6-3. Sequence alignment of human RNase 5 to human EGF and several 
RNase 5 homologues reveals
(A) T-coffee sequence alignment of human RNase 5 and human EGF. 
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 a highly conserved C-terminus.  
 
  
 
Figure 6-3. Sequence alignment of human RNase 5 to 
RNase 5 homologues reveals
 (B) T-coffee sequence alignment between different species of RNase 5, including 
human, mouse, horse, and cow, with human EGF.
 
94 
human EGF and several 
 a highly conserved C-terminus.  
  
  
 
Figure 6-4. Gln93 and Tyr94 within the C
EGFR binding.  
(A) Sequence alignment of human RNase 5 and human EGF. Asterisks represent 
100% conservation in all sequences; colons and dots represent p
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conservation. (B) Top: in vitro binding assay of N-EGFR-Fc with myc-tagged 
hRNase5 containing WT, C81A, C92A, Q93A, or Y94A mutant, pulled down using 
protein G beads. The relative density at myc-GST-hRNase5-WT was defined as 1 
using the ImageJ software program (version 1.38x; National Institutes of Health) to 
quantify the signals. Bottom: the quantified signal representing the fold ratio of 
hRNase5 bound to EGFR.  
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 6-5. The in vivo association of 
Gln93 of hRNase5 is mutated.
(A) Left: binding assay of N
transfected with WT and Q93A mutant, pulled down using protein G beads. 
Quantified ratio of hRNase5 bound 
analysis of 293T cells expressing myc
vector in the lysates and in culture media (secreted proteins).
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hRNase5 with EGFR is decreased while 
  
-EGFR-Fc with the collected media from 293T cells 
to EGFR is shown on the right. (B
-His-hRNase5 WT, Q93A, Y94A, or empty 
 
) Western blot 
  
 
 
 
 
Figure 6-6. hRNase5 plasmids containing the Cys mutants to alanine are not 
secreted in the media.  
(A) Binding assay of N
transfected with myc-GST
vector, pulled down using protein G beads. (
cells expressing WT, two of its point mutants, and empty 
and secreted proteins. 
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-EGFR-Fc with the collected media from 293T cells 
-hRNase5-WT, the indicated Cys mutants, and empty 
B) Immunoblotting analysis of 293T 
vector within the lysates 
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6.4 The binding affinity of human RNase 5 toward EGFR is within the range of 
known EGFR ligands with high binding affinity 
Next, we measured its binding affinity of hRNase5 for EGFR for comparison 
with EGF. Notably, the binding of hRNase5 to the N-terminal region of EGFR was 
relatively low (Figure 6-7A; ~70% binding ratio at 143 nM) compared with that of 
EGF (Figure 6-7B; ~100% binding ratio at 3.33 nM).  
For a more quantitative analysis, we performed enzyme-linked immunosorbent 
assay (ELISA) captured by an EGFR antibody with or without A431 cell lysates to 
determine the individual dissociation constants (KD). The estimated KD of EGF 
bound to EGFR was 1.87 nM (Figure 6-8A), which was consistent with published 
values (Bjorkelund et al., 2011; Ozcan et al., 2006). Under the same ELISA 
condition, the binding affinity (KD) of hRNase5 and bRNaseA for full-length EGFR 
was 36.6 nM (Figure 6-8B) and 885.3 nM (Figure 6-8C) or about 20-fold and 473-
fold less than that of EGF, respectively.  
It is worthwhile to mention that there are two classes of human EGFR ligands, 
including those with high affinity with a KD ranging between 1-100 nM (e.g,. EGF; 
HB-EGF) and those with low affinity with a KD greater than 100 nM (e.g., 
amphiregulin, KD = 350 nM; epigen, KD > 500 nM; murine epiregulin, KD = 2.8 µM) 
(Sanders et al., 2013). Thus, the KD of hRNase5 falls within the range of high affinity 
EGFR ligands. 
 
 
  
Figure 6-7. The binding of hRNase5 to the N
determined by using a pull
(A and B) Left: in vitro
concentrations of hRNase5
BSA served as a negative control. Right: Quantification of hRNase5
bound to EGFR against the individua
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-terminal region of EGFR 
-down assay. 
 binding assay of N-EGFR-Fc across a range of 
 (A) or EGF (B), pulled down using protein G beads. 
l input.  
is 
 (A) or EGF (B) 
  
Figure 6-8. Binding affinity of 
detected by ELISA with estimated K
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EGF, hRNase5, and bRNaseA toward EGFR are
D values.  
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Left: different concentrations of EGF (A), hRNase5 (B), and bRNaseA (C) were 
added to an EGFR-captured ELISA plate, with or without A431 cell lysates. Dotted 
line represents Bmax (maximum number of binding sites). Error bars represent SD. 
n = 2. Right: data derived using Scatchard plot analysis to determine KD values for 
interaction of EGFR with EGF, hRNase5, and bRNaseA. 
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Chapter 7 
Human RNase 5 contributes to  
cetuximab resistance  
in pancreatic cancer 
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Background and Rationale 
Cetuximab, a FDA approved anti-cancer drug that prevents EGFR from binding 
to its activating ligands, was proposed as a treatment modality for pancreatic cancer 
as EGFR signaling was recently identified to be essential for tumor initiation in 
pancreatic ductal adenocarcinoma (Ardito et al., 2012; Navas et al., 2012). However, 
clinical trials using cetuximab as adjuvant therapy with gemcitabine to treat 
pancreatic cancer did not improve the overall survival (Fensterer et al., 2013; Philip 
et al., 2010). We therefore asked whether hRNase5 plays a role in resistance to 
cetuximab therapy. 
 
Results 
7.1 hRNase5 enhances resistance to cetuximab therapy in pancreatic cancer 
Strikingly, we found that cetuximab-repressed cell migration and invasion of 
AsPC-1 pancreatic cancer cells was significantly increased in response to hRNase5 
treatment in a dose-dependent manner (Figures 7-1A and 7-1B). This suggests that 
hRNase5 is associated with cetuximab resistance.  
 
7.2 hRNase5-enhanced cell migration and invasion is neutralized by an anti-
hRNase5 antibody 
In contrast, addition of an anti-hRNase5 antibody neutralized the enhanced cell 
migration and invasion (Figures 7-2A and 7-2B). Together, the elevated level of 
serum hRNase5 observed in pancreatic cancer patients is likely sufficient to activate 
EGFR, which may in turn contribute to malignancy and resistance to cetuximab. 
  
 
 
 
Figure 7-1. Cetuximab-repressed cell migration and invasion 
derepressed by hRNase5
(A) Representative images from cell migration and invasion assays of AsPC
treated with or without cetuximab (10 µg/ml) and various concentration
hRNase5 (1, 3, 9 µg/ml). (
Error bars represent SD. n = 3. Statistical analysis was performed by Student’s t 
test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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 treatment in a dose-dependent manner
B) Quantification of cell migration and invasion from (
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.  
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Figure 7-2. hRNase5-enhanced cell migration and invasion is neutralized by 
an anti-hRNase5 antibody.
(A) Representative images from cell migration and invasion assays of AsPC
treated with cetuximab (10 µg/ml), hRNase5 (2 
(5 µg/ml), as indicated. (
Error bars represent SD. n = 3. Statistical analysis was performed by Student’s t 
test. **, P < 0.01; ***, P < 0.001. 
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Chapter 8 
Discussion and Future work 
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Our study has identified bovine RNase A and its human homologue RNase 5 
can serve as specific ligands to activate surface EGFR to initiate its downstream 
signaling network (Figure 8-1). It brings up one fundamental question that how 
these secretory ribonucleases can bind to the extracellular domain of EGFR in a 
specific manner. In our results, ribonuclease binding to EGFR can be impaired by 
C225 pretreatment, which suggests that ribonuclease binding region on EGFR 
extracellular domain could be very close to those bound by EGF. It is plausible that 
ribonuclease may exert certain structural similarity to EGF-like ligands, or 
ribonuclease could possess distinct and unknown conformation to be associated 
with EGFR as a complex. Both secondary and tertiary structure of ribonucleases 
and EGFR canonical ligands are well studied and established. Based on current 
knowledge about these two protein families, they are very different from each other 
in terms of disulfide bond linkage and crystal structure. Interestingly, there exist 
certain homology between human RNase 5 and human EGF in their primary 
sequence. Among these conserved residues, Q93 and Y94 residues of human 
RNase 5 are corresponding cognates to Q43 and Y44 of EGF protein, where Q43 
and Y44 have been shown to locate on the interface of EGF during its binding to 
EGFR although both residues are not essential to this interaction. Either Q93A or 
Y94A mutation can significantly decrease human RNase 5 binding to EGFR protein 
in vitro. It provides certain evidence to support that the binding region of human 
RNase 5 with EGFR may be similar to EGF with EGFR in a certain degree. To draw 
a more delicate and authentic picture of the complex formed by RNase and EGFR, 
we need to apply X-ray crystallography and NMR spectrometry to analyze their co- 
  
 
Figure 8-1. A proposed model for mammalian secretory ribonucleases to 
provoke EGFR signaling pathways and EMT
pancreatic cancer.  
Bovine RNase A (bRNaseA)
EGFR ligands to directly 
EGFR/ErbB2 hetero-dimer,
migration, invasion, and EMT
independent of RNases’ enzymatic activity
C225 resistance in pancreatic cancer cells
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crystal structure and compared them with well-resolved structure composed of 
EGFR and conventional ligands like EGF or HB-EGF.  More efforts to explore the 
structural insights of RNase-EGFR complex will provide novel viewpoints of EGFR 
activation because they may interact with each other through a way quite distinct 
from EGF-EGFR complex.  
 
Our research has revealed the first example that human RNase 5 can act as 
EGFR ligand independently of its enzyme activity. It is reasonable to speculate that 
other members of RNase A family may have similar function to serve as ligands for 
other receptors, in addition to their conventional roles as ribonucleases and 
participants in immunity. Notably, among the 13 members of RNase A family, 
RNase 9-13 are known to lose enzymatic activity as non-canonical ribonucleases.  
It would be interesting to test if any of them can be a cognate ligand to certain 
membrane receptor as well. A more systematic primary sequence alignment 
between RNase A family members and protein growth factors can be conducted to 
see if there exist any evolutional conservation among them. Moreover, ectopic 
expression of individual ribonuclease to stimulate recipient cells through conditioned 
medium combined with analysis through kinase antibody arrays will help to 
elucidate a potential role of other ribonuclease as a novel ligand to a known 
receptor. Future studies on this point of view may define certain ribonucleases as 
specific ligands to receptors to initiate cellular signaling pathways, and it can 
provide an explanation and biological role for those existing ribonucleases which 
lose their catalytic activities during evolution. On the other hand, it provides more 
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opportunities to find out new ligands for membrane receptors especially those 
without known ligands. Since ErbB2 is an orphan receptor without any known ligand 
to date, this approach may help to identify a first ligand of ErbB2 in the future.  
 
Previous studies have indicated human RNase 5 can bind to a 170-kDa 
membrane receptor of endothelial cells to trigger intracellular signaling and promote 
angiogenesis. Of note, EGFR is a 170-kDa receptor tyrosine kinase and in our 
study it is identified as the primary receptor of tumor cells to be associated with 
ribonuclease and initiate downstream signaling including AKT and ERK activation 
upon ribonuclease stimulation. Our work may provide an adequate answer to a 
long- term issue for years. According to previous reports, tumor-associated 
endothelial cells express higher level of EGFR and the EGFR signaling is required 
for their proliferation and angiogenic function. Since previously the unknown 170-
kDa membrane receptor was identified from endothelial cells, it would be worthwhile 
to investigate if human RNase 5 can bind to EGFR of tumor-associated endothelial 
cells, like we have observed with tumor cells. The experimental results will help to 
address if our current model can be applied to endothelial cells through a paracrine 
manner, since we have demonstrated that secreted ribonuclease can activate 
EGFR signaling in tumor cells through an autocrine mechanism. The same 
possibility also exist between tumor and stromal cells, because in pancreatic cancer 
the stromal cells play a crucial role for cancer aggressiveness and chemoresistance, 
and through a paracrine pathway that ribonuclease may also stimulate EGFR 
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signaling in tumor-associated stromal cells to aggravate pancreatic cancer 
tumorigenesis.  
 
We recently demonstrated that human RNase 5 can activate EGFR signaling in 
pancreatic cancer cells. In addition, the EGFR activation is essential to human 
RNase 5-provoked cell migration and invasion. Animal studies including pancreatic 
cancer orthotopic model or transgenic mice with KRASG12D and p53 knockout can 
be conducted in the future to see if human RNase 5 can contribute to pancreatic 
cancer occurrence and progression. Those mouse models will help us to investigate 
if RNase 5 level is elevated in the initiation or early phase of pancreatic cancer 
progression. Accordingly, human RNase 5 level in patient serum is significantly 
elevated compared to normal donors, and it may confer tumor cells more insensitive 
to C225 treatment but more sensitive to TKI therapy. A proposed combinational 
therapy of C225 together with anti-human RNase 5 neutralization antibody or TKI 
treatment using serum RNase 5 level as a predictive biomarker based on our study 
can be examined in adequate animal models to see if it can be beneficial to clinical 
practice in the future.  
 
In our work, secretory ribonuclease including bovine RNase A and human 
RNase 5 can promote cell migration and invasion, while they cannot induce cell 
proliferation on 2D culture like conventional EGFR ligands including EGF and HB-
EGF. These partial overlapped but distinct biological effects between these two 
families of ligands implicate that RNases may trigger certain signaling pathways and 
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gene expression patterns different from typical EGFR ligands. An outstanding 
question is how those ligands can provoke different biological functions and gene 
expression by binding to and activating the same receptor. More comprehensive 
analysis of gene expression such as cDNA microarray and RNA sequencing can be 
performed in the future to characterize and compare gene expression signatures 
induced by RNases and conventional EGFR ligands.  It will provide a molecular 
basis for us to study how these ligands can trigger different biological effects 
through the same receptor activation. Since EGFR activation can promote an array 
of biological function including anchorage-independent growth, angiogenesis and 
stem-like properties, it would be worthwhile to examine if RNases can trigger these 
particular effects through activating EGFR signaling. More efforts to answer these 
types of questions will provide more solid evidence to depict the biological role of 
RNase A and RNase 5 as ligands of EGFR in physiology and cancer biology. 
 
Human RNase 5 is characterized to promote angiogenesis both in vitro and in 
vivo. In our hands, it can stimulate pancreatic cancer cell migration and invasion, 
leading to EMT process through EGFR activation. During the process, the tumor 
cell viability is not affected by ribonuclease treatment in a significant level. However, 
the same stimulation may exert different impact to other type of cells. An interesting 
finding was made in previous studies that human ribonuclease 5 can suppress 
immune cells including B and T cell proliferation in vitro, and the same feature was 
also observed with bovine RNase A treatment although the effect is milder 
(Matousek et al., 1995; Soucek et al., 1999; Sun et al., 2013). It would be interesting 
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to ask if increased ribonuclease expression can interfere or impair immune function 
in vivo, especially during the tumor initiation and progression. Based on previous 
studies from other groups and our finding, ribonuclease activity and human RNase 
5 expression could be elevated in pancreatic cancer patient serum, and it may 
aggravate cancer progression through two arms: one arm is to activate EGFR 
signaling of tumor cells to increase their motility and aggressiveness through 
autocrine or paracrine manner, and the other arm is to block appropriate immune 
response to eliminate tumor cells. This hypothesis is in need of more experiments 
both in vitro and in vivo to validate in the future.  
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